Evidence Hub

Study of the effect of antihistamine active pharmaceutical ingredients on the rate of dopamine oxidation in vitro

Владислав Віталійович Удовицький, Р. О. Смішко, Вікторія Віталіївна Лижнюк, Андрій Гой, Володимир Іванович Бессарабов

Farmatsevtychnyi zhurnal, 2024

2 citations

Abstract

Parkinson's disease is one of the most common neurodegenerative diseases characterized by degeneration of dopaminergic neurons in the midbrain and a decrease in dopamine levels. Insufficient amounts of this neurotransmitter lead to such characteristic movement disorders as resting tremor, rigidity, bradykinesia, and postural instability. Levodopa, as a dopamine precursor, is the main drug for the symptomatic treatment of this disorder. However, in their complex metabolism, both dopamine and levodopa can undergo many transformations, most of which are caused by the action of free radicals generated as a result of oxidative stress. This process plays an important role in the progression of Parkinson's disease. Therefore, it is important to prevent the oxidation and degradation of dopamine and levodopa.

As a result of the analysis of scientific and literary sources, it was found that antihistamines can be considered as potential candidates for use in the combination pharmacotherapy of Parkinson's disease.

The aim of the study was to investigate the pleiotropic properties of the antihistamine active pharmaceutical ingredients desloratadine and levocetirizine in vitro in a model chemical system of dopamine oxidation. The kinetic study of the activity of antihistamine compounds in relation to dopamine oxidation was performed spectrophotometrically. The quantitative expression of the reaction rates was performed by calculating the first-order rate constant.

It was found that…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free